196 related articles for article (PubMed ID: 8474322)
1. Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimer.
Glueck CJ; Glueck HI; Tracy T; Speirs J; McCray C; Stroop D
Metabolism; 1993 Feb; 42(2):236-46. PubMed ID: 8474322
[TBL] [Abstract][Full Text] [Related]
2. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia.
Glueck CJ; Glueck HI; Tracy T; Speirs J; Stroop D
Metabolism; 1993 Nov; 42(11):1410-9. PubMed ID: 8231835
[TBL] [Abstract][Full Text] [Related]
3. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
Glueck CJ; Glueck HI; Stroop D; Speirs J; Hamer T; Tracy T
J Lab Clin Med; 1993 Oct; 122(4):412-20. PubMed ID: 8228555
[TBL] [Abstract][Full Text] [Related]
4. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity.
Glueck CJ; Glueck HI; Hamer T; Speirs J; Tracy T; Stroop D
Am J Med Sci; 1994 May; 307(5):317-24. PubMed ID: 7909648
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting fibrinolytic potential: cardiovascular fitness, body composition, and lipoprotein(a).
Szymanski LM; Durstine JL; Davis PG; Dowda M; Pate RR
Metabolism; 1996 Nov; 45(11):1427-33. PubMed ID: 8931650
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic parameters, lipid status and lipoprotein(a) in ischemic stroke patients.
Vucković BA; Djerić MJ; Ilić TA; Canak VB; Kojić-Damjanov SLj; Zarkov MG; Cabarkapa VS
Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():12-7. PubMed ID: 20229676
[TBL] [Abstract][Full Text] [Related]
7. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?
Glueck CJ; Glueck HI; Mieczkowski L; Tracy T; Speirs J; Stroop D
Thromb Haemost; 1993 May; 69(5):460-5. PubMed ID: 8322268
[TBL] [Abstract][Full Text] [Related]
8. [Relationship of lipoprotein(a) to fibrinolytic activities in healthy subjects].
Xiong X; Zhao S; Wang Z; Lo L; Huang Q
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(6):555-7. PubMed ID: 10806767
[TBL] [Abstract][Full Text] [Related]
9. Does Lp(a) lipoprotein inhibit the fibrinolytic system?
Halvorsen S; Skjønsberg OH; Berg K; Ruyter R; Godal HC
Thromb Res; 1992 Nov; 68(3):223-32. PubMed ID: 1471070
[TBL] [Abstract][Full Text] [Related]
10. Relationship of lipoprotein(a) to variables of coagulation in hypertensive subjects.
Sechi LA; De Marchi S
J Investig Med; 2001 Jan; 49(1):12-20. PubMed ID: 11217142
[TBL] [Abstract][Full Text] [Related]
11. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Atherosclerosis Risk in Communities (ARIC) Study Investigators.
Shahar E; Folsom AR; Salomaa VV; Stinson VL; McGovern PG; Shimakawa T; Chambless LE; Wu KK
Circulation; 1996 Jun; 93(11):1970-5. PubMed ID: 8640970
[TBL] [Abstract][Full Text] [Related]
12. Dietary regulation of fibrinolytic factors.
Mehrabian M; Peter JB; Barnard RJ; Lusis AJ
Atherosclerosis; 1990 Sep; 84(1):25-32. PubMed ID: 2147372
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
14. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
Thøgersen AM; Söderberg S; Jansson JH; Dahlén G; Boman K; Nilsson TK; Lindahl B; Weinehall L; Stenlund H; Lundberg V; Johnson O; Ahrén B; Hallmans G
Eur J Cardiovasc Prev Rehabil; 2004 Feb; 11(1):33-40. PubMed ID: 15167204
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic Dysregulation in Total Joint Arthroplasty Patients: Potential Clinical Implications.
Guler N; Burleson A; Syed D; Banos A; Hopkinson W; Hoppensteadt D; Rees H; Fareed J
Clin Appl Thromb Hemost; 2016 May; 22(4):372-6. PubMed ID: 26207021
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo.
Biemond BJ; Friederich PW; Koschinsky ML; Levi M; Sangrar W; Xia J; Büller HR; ten Cate JW
Circulation; 1997 Sep; 96(5):1612-5. PubMed ID: 9315555
[TBL] [Abstract][Full Text] [Related]
17. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
18. Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
Suefuji H; Ogawa H; Yasue H; Imoto N; Sakamoto T; Miyao Y; Kaikita K; Soejima H; Nishiyama K
Coron Artery Dis; 1996 Feb; 7(2):167-72. PubMed ID: 8813450
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
Folsom AR; Aleksic N; Park E; Salomaa V; Juneja H; Wu KK
Arterioscler Thromb Vasc Biol; 2001 Apr; 21(4):611-7. PubMed ID: 11304480
[TBL] [Abstract][Full Text] [Related]
20. [Selected new atherosclerosis risk factors and markers of fibrinolysis in children and adolescents with obesity, hypertension and diabetes].
Głowińska B; Urban M; Koput A; Galar M
Przegl Lek; 2003; 60(1):12-7. PubMed ID: 12884639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
